New cocktail of immune drugs takes on tough colorectal cancer
NCT ID NCT06149481
First seen Nov 01, 2025 · Last updated Apr 27, 2026 · Updated 25 times
Summary
This study tests a combination of up to four experimental drugs (retifanlimab, TriAdeno vaccine, N-803, and SX-682) in adults with metastatic colorectal cancer that has spread and not responded to prior treatments. The goal is to see if the immune-boosting cocktail can shrink tumors or slow the disease. Participants receive the drugs over up to 2 years, with regular monitoring and two tumor biopsies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.